Amgen Inc. vs Geron Corporation: Annual Revenue Growth Compared

Amgen Inc. vs Geron Corporation: A Tale of Divergent Growth

In the competitive landscape of biotechnology, Amgen Inc. and Geron Corporation present a fascinating study in contrasts. Over the past decade, Amgen has consistently demonstrated robust revenue growth, with a remarkable 40% increase from 2014 to 2023. This growth trajectory underscores Amgen's strategic prowess and market dominance. In stark contrast, Geron Corporation's revenue has experienced significant volatility, peaking in 2015 but subsequently declining by over 90% by 2023. This disparity highlights the challenges faced by smaller biotech firms in sustaining growth amidst market pressures. The data reveals a compelling narrative of resilience and adaptation, as Amgen continues to capitalize on its established market position, while Geron navigates the complexities of innovation and competition. As the biotech industry evolves, these companies exemplify the diverse paths to success and the inherent risks of the sector.